Connect with us
  • Elysium

Dementia

Alzheimer’s Research UK receives diagnostics funding boost

Alzheimer’s Research UK to receive up to US$2m in funding to produce a digital toolkit of apps and wearable technology aimed at aiding earlier diagnosis.

Published

on

A woman making a jigsaw puzzle about Alzheimer's disease. The jigsaw is of a white brain on a wooden surface. It has one piece missing which is to the side of the brain.

The US Alzheimer’s Drug Discovery Foundation (ADDF) has announced up to US$2m of funding for a collaborative research initiative led by Alzheimer’s Research UK to develop a digital toolkit of apps and wearables to detect the earliest stage of Alzheimer’s.

The funding awarded to the Early Detection of Neurodegenerative Diseases (EDoN) initiative is part of the ADDF Diagnostics Accelerator (DxA), which challenges the global research community to innovate new diagnostic technologies for dementia and Alzheimer’s.

Early detection of neurodegenerative diseases

EDoN is a project led by Alzheimer’s Research UK which combines global experts in data science, digital technology and neurodegeneration. It monitors sleep, fine motor control, heart rate, speech and brain activity to develop digital signs of early disease that could improve dementia research efforts in the future.

EDoN aims to streamline efforts to collect, integrate and analyse a wealth of digital, clinical and health data to help identify the disease earlier.

The data can be compiled to build machine learning models to identify patterns of early disease-specific to different neurodegenerative diseases.

The project aims to incorporate the best measures into an inexpensive and easy-to-use digital toolkit. This will likely be a combination of apps, wearable or mobile devices and software.

Funding and research

The funding will allow the team of researchers to collect digital data from over 600 people who are currently involved in two population-based cohort studies in Australia.

The participants are asked to wear a headband to measure sleep and brain activity, an activity tracker to register heart rate and physical activity.

This will be combined with a smartphone app that measures cognitive function such as speech or fine motor control. This data will be compared to clinical data from the cohorts to help researchers identify the digital measures linked to biological changes.

Participants in the study include people with different levels of Alzheimer’s disease, those with mild cognitive impairment and cognitively healthy volunteers. This will allow researchers to view a wide range of responses across a spectrum of cognitive health. They will follow the individuals involved over time identifying any changes that occur.

Diagnostics accelerator

The diagnostics Accelerator provides funding to increase the development of affordable and accessible diagnostic tools and biomarkers for the disease. The initiative currently funds over 30 projects around the world including a number of blood tests and eye scanning techniques. These tests monitor the early biological changes due to Alzheimer’s disease.

These changes may be undetectable to the human eye but may be picked up by digital technologies.

Read More: Engineers develop ultrasound patch to monitor blood flow

Dr Zoe Kourtzi, scientific director and chair of EDoN Steering Committee, said: “Around the world, there are 50 million people living with dementia — a number that is only set to rise. Global efforts to tackle the diseases that cause dementia are currently hamstrung by our inability to detect them early enough. Digital technology holds enormous potential to put us on the front foot when it comes to identifying diseases like Alzheimer’s earlier, and EDoN is working to make that happen.

“Accurate and cost-effective tools for detecting early neurodegenerative disease will provide essential insight into fundamental disease mechanisms, improve clinical diagnosis and enable existing and future interventions to be given earlier when they have the best possible chance of success.

“We are very excited to be working with the ADDF through the Diagnostics Accelerator. The funding will allow us to identify which digital measures have the most potential for early detection. The richer the data we can collect, and the more precise the algorithms we can develop, the faster we can move towards a digital toolkit that we hope will ultimately help doctors detect diseases like Alzheimer’s 10-15 years earlier than we can today.”

Read more: Seven devices that are revolutionising dementia care

Dementia

Young-onset Alzheimer’s prevention trial to launch

The Primary Prevention Trial will target participants up to 25 years before the expected onset of dementia

Published

on

An international clinical trial is being launched aimed at preventing young-onset Alzheimer’s disease in people genetically destined to develop the illness. 

Unlike most other Alzheimer’s prevention trials, this will enrol people before the disease has taken hold, up to 25 years before the expected onset of dementia. 

The Primary Prevention Trial, led by Washington University School of Medicine in St. Louis, will investigate whether gantenerumab — an investigational antibody under development for Alzheimer’s disease by Roche and Genentech — can clear a key Alzheimer’s protein called amyloid beta, and slow or stop the disease. 

Amyloid is the chief component of plaques that dot the brains of people with the disease.

Many scientists suspect the disease originates from the buildup of amyloid plaques in the brain that start to develop up to two decades before symptoms of dementia begin.

“Overwhelming evidence suggests that the most effective way to slow or stop amyloid beta is to prevent it from building up in the first place, but most of the drugs targeted to this protein have been tested in people who already have at least some early signs of the disease, such as memory loss – when the disease is far enough along that reducing amyloid alone isn’t likely to stop it,” said Dr Eric McDade, an associate professor of neurology and the trial’s principal investigator. 

“We’ll be recruiting participants as young as 18. In many ways, this trial will be a necessary test of the amyloid hypothesis, which has had a major influence on Alzheimer’s research and drug development over the past 30 years.”

The new trial involves families with rare genetic mutations that cause Alzheimer’s at a young age – typically in a person’s 50s, 40s or even 30s. 

A parent with such a mutation has a 50 per cent chance of passing the genetic mutation to a child, and any child who inherits the mutation is all but guaranteed to develop symptoms of dementia near the same age as his or her parent. 

This certainty gives researchers an opportunity to evaluate the effectiveness of drugs designed to prevent Alzheimer’s.

More than $130million has been earmarked for the trial, including grants totalling an estimated $97.4million from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), $14million from the Alzheimer’s Association and the GHR Foundation, and up to $11.5million from longtime Washington University benefactor Joanne Knight of St. Louis and family, who have long supported Alzheimer’s research at Washington University. In addition, the university has pledged to raise an additional $6.5 million. 

The trial is being conducted in close partnership with Roche and Genentech, which also is providing significant funding.

“We are thrilled to be part of this important clinical trial in one of the earliest stages of Alzheimer’s studied to date,” said Dr Rachelle Doody, global head of neurodegeneration at Roche and Genentech. 

“Our vision has always been to detect Alzheimer’s early, before damage in the brain is irreversible, offering tools and treatment all along the journey for people at risk of the disease. 

“Close collaboration between industry, academia and patients is so critical to achieve this and tackle the complex challenge of this disease.”

The trial will recruit people with rare, early-onset forms of the disease, but the results also will further understanding of Alzheimer’s overall, which could benefit the millions of people living with the more common form, which affects people later in life. 

Dr McDade and his team are studying about 230 participants from families that carry genetic mutations that lead to early-onset Alzheimer’s disease. 

The participants come from sites on five continents and have no or very few amyloid deposits. 

The trial will test gantenerumab over four years, with a goal of determining whether early treatment will prevent the buildup of the toxic protein.

Continue Reading

Brain injury

COVID ‘can cause more signs of brain damage than Alzheimer’s’

New research found higher levels of seven markers of neurodegeneration in hospitalised COVID patients

Published

on

Patients hospitalised for COVID-19 had higher levels over the short term of blood proteins known to rise with neurological damage than non–COVID-19 patients diagnosed with Alzheimer’s disease, a new study has found.

The research – conducted over two months early in the COVID-19 pandemic – found higher levels of seven markers of brain damage, or neurodegeneration, in patients with COVID-19 with neurological symptoms than those without them, and much higher levels in patients that died in the hospital than in those discharged and sent home.

A second analysis by the team from NYU Grossman School of Medicine found that a subset of the damage markers in patients hospitalised with COVID-19, over the short term, were significantly higher than in patients diagnosed with Alzheimer’s disease, and in one case more than twice as high.

“Our findings suggest that patients hospitalised for COVID-19, and especially in those experiencing neurological symptoms during their acute infection, may have levels of brain injury markers that are as high as, or higher than, those seen in people who have Alzheimer’s disease,” says lead author Dr Jennifer A. Frontera, professor in the Department of Neurology at NYU Grossman School of Medicine.

“Traumatic brain injury, which is also associated with increases in these biomarkers, does not mean that a patient will develop Alzheimer’s disease or related dementias later on, but does increase the risk of it,” says senior author Dr Thomas M. Wisniewski, the Gerald J. and Dorothy R. Friedman Professor in the Department of Neurology and director of the Center for Cognitive Neurology at NYU Langone. 

“Whether that kind of relationship exists in those who survive severe COVID-19 is a question we urgently need to answer with ongoing monitoring of these patients.”

The study, conducted from March to May 2020, identified 251 people who, although 71 years on age on average, had no record or symptoms of cognitive decline or dementia before being hospitalised for COVID-19. 

These patients were then divided into groups with and without neurological symptoms during their acute COVID-19 infection, when patients either recovered and were discharged, or died.

The research team also, where possible, compared marker levels in the COVID-19 group to patients in the clinical core cohort of NYU Langone’s Alzheimer’s Disease Research Center, an ongoing, long-term study at NYU Langone Health. 

None of these 161 control patients (54 cognitively normal, 54 with mild cognitive impairment, and 53 diagnosed with Alzheimer’s disease) had COVID-19. Brain injury was measured using single-molecule array (SIMOA) technology, which can track the minute blood levels of neurodegeneration markers in picograms (one trillionth of a gram) per millilitre of blood (pg/ml), where older technologies could not.

Three of the study markers—ubiquitin carboxy-terminal hydrolase L1 (UCHL1), total tau, and phosphorylated-tau-181 (ptau181)—are known measures of the death or disabling of neurons, the cells that enable nerve pathways to carry messages. 

Levels of neurofilament light chain increase with damage to axons, which are extensions of neurons. Glial fibrillary acidic protein (GFAP) is a measure of damage to glial cells, which support neurons. Amyloid beta 40 and 42 are proteins known to build up in people who have Alzheimer’s disease. 

Past study results argue that total tau and ptau181 are also specific measures of Alzheimer’s disease, but their role in the disease remains a matter of debate.

Blood markers in the COVID-19 patient group were measured in blood serum (the liquid part of blood that has been made to clot), while those in the Alzheimer’s disease study were measured in plasma (the liquid blood fraction that remains when clotting is prevented). 

For technical reasons, the difference meant that neurofilament light chain, GFAP, and UCHL1 levels could be compared between the COVID-19 group and patients in the Alzheimer’s disease study, but total tau, ptau181, amyloid beta 40, and amyloid beta 42 could only be compared within the COVID-19 patient group (neuro symptoms or not; death or discharge).

Further, the main measure of neurological damage in patients with COVID-19 was toxic metabolic encephalopathy, or TME, with symptoms that range from confusion to coma, and caused during severe infections by toxins generated as the immune system overreacts (sepsis), kidneys fail (uremia), and oxygen delivery is compromised (hypoxia). 

Specifically, the average percentage increase in levels of the seven markers for hospitalised patients with TME compared to those without neurological symptoms was 60.5 per cent. 

For the same markers within the COVID-19 group, average percentage increase when comparing those successfully discharged home from the hospital to those who died in the hospital was 124 per cent.

A secondary set of findings came from comparing neurofilament light chain, GFAP, and UCHL1 levels in the serum of people with COVID-19 against levels of the same markers in the plasma of non–COVID-19 Alzheimer’s disease patients. 

Neurofilament light chain was, over the short-term, 179 per cent higher (73.2 versus 26.2 pg/ml) in patients with COVID-19 than those with Alzheimer’s disease. GFAP was 65 per cent higher (443.5 versus 275.1 pg/ml) in patients with COVID-19 patients than those with Alzheimer’s disease, while UCHL1 was 13 per cent higher (43 versus 38.1 pg/ml).

Continue Reading

Dementia

Dementia protein changes discovered in terminal childhood disease

‘These findings challenge the view that changes to the brain that underlie these forms of dementia are merely age-associated’

Published

on

A world-first study has revealed that protein changes seen in dementia are also present in a terminal childhood disease. 

The pioneering research found that the brains of infants who passed away with an extremely rare genetic condition, Krabbe disease, have similar changes to those seen in two age-related brain diseases, dementia with Lewy bodies and Parkinson’s disease.

The study, from Newcastle University and funded by Alzheimer’s Research UK, shows alpha-synuclein has the potential to spread throughout the brain. 

Dementia with Lewy bodies (DLB) and Parkinson’s disease are both neurodegenerative diseases associated with older age. 

In both diseases, a protein called alpha-synuclein builds up in the brain into structures called Lewy bodies, causing damage to nerve cells.

In contrast, Krabbe disease is a rare inherited childhood disorder – with only one case in every 100,000 births. 

The disease destroys the protective coating surrounding nerve cells in the brain and throughout the nervous system. It is caused by a mutation in the GALC gene, with symptoms showing within the first few months of life.

Sadly, the disease typically leads to death in those affected by the age of two.

The team at Newcastle studied postmortem brain tissue of four infants who died of Krabbe disease. While they did not identify Lewy bodies in the brain tissue of those infants, they did identify changes to the protein alpha-synuclein that are normally associated with DLB and Parkinson’s disease.

In particular, the researchers noted that the alpha-synuclein protein in Krabbe disease had the ability to stick together and spread through the brain, a key change associated with dementia with Lewy bodies and Parkinson’s disease that is thought to drive the progression of both diseases.

Dr Daniel Erskine, Alzheimer’s Research UK Research Fellow at Newcastle University, who is an expert in Lewy bodies and led the study, said: “Looking at the brains of four infants with Krabbe disease compared to four infants without Krabbe disease, we performed a series of experiments to establish the behaviour of the alpha-synuclein protein. 

Dr Daniel Erskine

“We found that alpha-synuclein in Krabbe disease shared key qualities that are normally only associated with age-associated neurodegenerative disease like dementia with Lewy bodies.

“This phenomenon has only been reported previously in the brains of older people with neurodegenerative diseases, so seeing it in the brains of these infants is highly remarkable.

“These findings challenge the view that changes to the brain that underlie these forms of dementia are merely age-associated, but are instead the result of dysfunction of specific biological pathways. 

“This is an important message, as while we cannot stop ageing, we can potentially fix something that is not working properly.

“These research findings have only been made possible from the support of the families donating their loved ones’ brains for research and I would like to pay tribute to them for their generosity in helping others in a time of unparalleled grief.

“Thankfully, Krabbe disease is a relatively rare condition, however it is devastating for the families affected. Dementia with Lewy bodies affects roughly 100,000 people in the UK.

“Building on these findings to help develop new drugs that target this common biological pathway could change the lives of people with both conditions.”

Dr Rosa Sancho, head of research at the charity Alzheimer’s Research UK, said: “In dementia with Lewy bodies, the protein alpha-synuclein forms clumps called Lewy bodies inside brain nerve cells. 

“While Lewy bodies were not found in the brains of infants in this study, researchers have shown for the first time that alpha-synuclein had a similar capacity to spread through the brain in Krabbe disease.

“At Alzheimer’s Research UK we often hear dementia dismissed as a normal part of ageing. 

“We know dementia is caused by brain diseases, and this research offers more evidence that the disease that cause dementia are caused by biological processes going awry rather than as a by-product of old age.

“Learning about the diseases that cause dementia from other neurodegenerative conditions and sharing this knowledge with other fields is important. 

“We’re incredibly grateful to the families of those whose brains were studied in this research, and who made this important discovery possible.”

Continue Reading

Newsletter



Get the NR Times update

Trending